PSOREAL – Managing PSOriasis in the REAL World

Overview

Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar® (calcipotriol/betamethasone dipropionate).

Full Title of Study: “One-year Prospective, Observational Study of the Journey of Patients With Plaque Psoriasis Prescribed Calcipotriol/Betamethasone Aerosol Foam or Other Topical Therapy”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2023

Detailed Description

This multinational study aims to describe current treatment patterns and outcomes in the diversity of the real life setting: local differences in access to drugs and current treatment practices, and regional cultural differences, covering adult patients of all backgrounds, sex, socio-economic standing, health background, comorbidity and co-medication. A total of around 400 real-life prescribers in 3-8 countries are expected to participate over the years, with each country contributing data to the study for around 2 years, starting data collection within the first year after local market introduction of Enstilar®.

The real-life prescribing and utilization patterns of topical prescription products approved for treatment of psoriasis vulgaris in the individual participating countries will be mapped and performance of the products in real life will be investigated based primarily on baseline data from investigators and patient reported data contributed by the individual patient for 1 year. Patients are expected to enter data on their electronic device at baseline and at times of treatment changes and other key events, and investigators are expected to contribute data after each contact with the patient.

Patients will be approached for informed consent to participate in the study after their individual treatment plan has been decided. The study aims to include two patients on other topical treatment for every patient planned to receive Enstilar® in order to ensure a sufficient sample of Enstilar® treated patients to capture the diversity of real-life prescription patterns in patients not on Enstilar®, and to allow for sufficiently powered comparisons between Enstilar® and other real-world treatment strategies. A systematic approach will be used to select eligible patients to be approached for study participation in order to minimize selection bias and control seasonal variations.

Interventions

  • Drug: Enstilar® aerosol foam
    • Treatment according to local labelling
  • Drug: Other topical
    • Treatment according to local practise

Arms, Groups and Cohorts

  • Enstilar®
    • Patients for whom a new treatment strategy has been decided which involves start of topical treatment with Enstilar® according to the current local labelling
  • Other topical
    • Patients for whom a new treatment strategy has been decided which involves start of topical treatment not including Enstilar®

Clinical Trial Outcome Measures

Primary Measures

  • PaGA
    • Time Frame: 4 weeks
    • Patient reported Global Assessment
  • Itch
    • Time Frame: 1 week
    • Itch dimension of Psoriasis Symptom Inventory (PSI) questionnaire
  • Switch
    • Time Frame: 1 year
    • Time to switch of topical treatment strategy
  • Flare-up
    • Time Frame: 1 year
    • Time to first flare-up after initial treatment completion

Participating in This Clinical Trial

Inclusion Criteria

  • Adult age
  • Psoriasis vulgaris
  • Plaques on the body (trunk and/or extremities) of at least mild severity at time of inclusion
  • Decision to prescribe a topical psoriasis treatment for body use where the prescription is NOT a routine renewal of the prescription of an ongoing therapy
  • Signed and dated informed consent
  • Willingness and ability to enter personal disease and treatment information onto a secure webpage during the one year individual study period, using their existing access to a PC or electronic device and a personal access code.

Exclusion Criteria

  • Participation in the active treatment phase of a clinical trial
  • Previous enrollment in the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • LEO Pharma
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Kreesten M Madsen, MD, PhD, Study Director, LEO Pharma
  • Overall Contact(s)
    • Lise S Skov-Ettrup, PhD, +45 31471491, ogvdk@leo-pharma.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.